AtaiBeckley Inc. ATAI shares are up on Wednesday following the announcement of promising Phase 2a results for its ...
Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohorts; Durable responses ...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated ...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 ...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 ...
View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.
That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...
Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...
Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results